secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0000950170-23-002652
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences raises $15.6M in public offering; believes it regains Nasdaq compliance
--------------------------------------------------------------------------------

- Gross proceeds of ~$15.6M from sale of 2.89M shares and pre-funded warrants, plus 6.45M warrants at $5.36 exercise price.
- Net proceeds of ~$14.1M to fund REVTx-100 and REVTx-300 development, including Phase 1a/1b studies and manufacturing.
- Company believes it now meets Nasdaq's $2.5M stockholders' equity requirement; bid price compliance at 9 of 10 consecutive days.
- Officers and directors subject to 90-day lock-up; institutional investors have leak-out limiting sales to 25% of trading volume until April 10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/0000950170-23-002652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/revb-20230209.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer